Jean Y. Gouzi

Jean Y. Gouzi

Auto-generated profile, based on publicly available information

Jean Y. Gouzi

Institute for Fundamental Biomedical Research, and

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2005 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
CMChristel Moog-Lutz
Christel Moog-Lutz
JDJoffrey Degoutin
Joffrey Degoutin
JGJean Y. Gouzi
Jean Y. Gouzi
YFYvelyne Frobert
Yvelyne Frobert
NCNicole Brunet-De Carvalho
Nicole Brunet-De Carvalho
MVMarc Vigny
Marc Vigny
Anaplastic lymphoma kinase (ALK) is a receptor tyrosine kinase that is transiently expressed in specific regions of the central and peripheral nervous systems, suggesting a role in its normal development and function. The nature of the cognate ligands of ALK in vertebrate is still a matter of debate. We produced a panel of monoclonal antibodies (mAbs) directed against the extracellular domain of the human receptor. Two major species of ALK (220 and 140 kDa) were identified in transfected cells, and the use of our mAbs established that the 140-kDa species results from a cleavage of the 220-kDa form. Two mAbs, in the nm range, induced the differentiation of PC12 cells transiently transfected with ALK. In human embryonic kidney 293 cells stably expressing ALK, these two mAbs strongly activated the receptor and subsequently the mitogen-activated protein kinase pathway. We further showed for the first time that activation of ALK also resulted in a specific activation of STAT3. In contrast, other mAbs presented the characteristics of blocking antibodies. Finally, in these cell systems, a mitogenic form of pleiotrophin, a proposed ligand of ALK, failed to activate this receptor. Thus, in the absence of clearly established ligand(s) in vertebrates, the availability of mAbs allowing the activation or the inhibition of the receptor will be essential for a better understanding of the biological roles of ALK.

15 September 2011 in PLOS Genetics
Verified
Journal Article
Open access
PDF file
JGJean Y Gouzi
Jean Y Gouzi
AMAnastasios Moressis
Anastasios Moressis
JWJames A Walker
James A Walker
AAAnthi A Apostolopoulou
Anthi A Apostolopoulou
RPRuth H Palmer
Ruth H Palmer
Efthimios M.C. SkoulakisEfthimios M.C. Skoulakis
Efthimios M.C. Skoulakis
Anaplastic Lymphoma Kinase (Alk) is a Receptor Tyrosine Kinase (RTK) activated in several cancers, but with largely unknown physiological functions. We report two unexpected roles for the Drosophila ortholog dAlk, in body size determination and associative learning. Remarkably, reducing neuronal dAlk activity increased body size and enhanced associative learning, suggesting that its activation is inhibitory in both processes. Consistently, dAlk activation reduced body size and caused learning deficits resembling phenotypes of null mutations in dNf1, the Ras GTPase Activating Protein-encoding conserved ortholog of the Neurofibromatosis type 1 (NF1) disease gene. We show that dAlk and dNf1 co-localize extensively and interact functionally in the nervous system. Importantly, genetic or pharmacological inhibition of dAlk rescued the reduced body size, adult learning deficits, and Extracellular-Regulated-Kinase (ERK) overactivation dNf1 mutant phenotypes. These results identify dAlk as an upstream activator of dNf1-regulated Ras signaling responsible for several dNf1 defects, and they implicate human Alk as a potential therapeutic target in NF1. Neurofibromatosis-1 (NF1) syndrome is a common (1/3,000 births) genetic disorder affecting multiple organ systems, including the nervous system. Its clinical features include short stature, learning disabilities, and several types of benign and malignant tumors. NF1 is caused by mutations that inactivate the NF1 gene, a crucial negative regulator of Ras signaling. Although unregulated Ras signaling is a hallmark of NF1, the specific Ras signaling pathways responsible for disease development remain largely unknown. The Drosophila and human Nf1 genes are highly conserved; and, as in patients, mutant flies are smaller than usual and present deficient learning. Here, we identified the Drosophila Receptor Tyrosine Kinase dAlk as a negative regulator of organismal growth and olfactory learning. We show that excessive dAlk activation results in growth and learning defects similar to those of Nf1 mutants. Genetic suppression studies and pharmacological inhibition indicate dAlk as a critical upstream activator of Nf1-regulated neuronal Ras/ERK signals that contribute to size determination and learning. Importantly, our results strongly suggest that Alk represents a novel, highly specific, and promising therapeutic target in human NF1.

21 November 2013 in PLOS Genetics
Verified
Journal Article
Open access
PDF file
JWJames A Walker
James A Walker
JGJean Y Gouzi
Jean Y Gouzi
JLJennifer B Long
Jennifer B Long
SHSidong Huang
Sidong Huang
RMRobert C Maher
Robert C Maher
ABAndré Bernards
André Bernards
Neurofibromatosis type 1 (NF1), a genetic disease that affects 1 in 3,000, is caused by loss of a large evolutionary conserved protein that serves as a GTPase Activating Protein (GAP) for Ras. Among Drosophila melanogaster Nf1 (dNf1) null mutant phenotypes, learning/memory deficits and reduced overall growth resemble human NF1 symptoms. These and other dNf1 defects are relatively insensitive to manipulations that reduce Ras signaling strength but are suppressed by increasing signaling through the 3′-5′ cyclic adenosine monophosphate (cAMP) dependent Protein Kinase A (PKA) pathway, or phenocopied by inhibiting this pathway. However, whether dNf1 affects cAMP/PKA signaling directly or indirectly remains controversial. To shed light on this issue we screened 486 1st and 2nd chromosome deficiencies that uncover >80% of annotated genes for dominant modifiers of the dNf1 pupal size defect, identifying responsible genes in crosses with mutant alleles or by tissue-specific RNA interference (RNAi) knockdown. Validating the screen, identified suppressors include the previously implicated dAlk tyrosine kinase, its activating ligand jelly belly (jeb), two other genes involved in Ras/ERK signal transduction and several involved in cAMP/PKA signaling. Novel modifiers that implicate synaptic defects in the dNf1 growth deficiency include the intersectin-related synaptic scaffold protein Dap160 and the cholecystokinin receptor-related CCKLR-17D1 drosulfakinin receptor. Providing mechanistic clues, we show that dAlk, jeb and CCKLR-17D1 are among mutants that also suppress a recently identified dNf1 neuromuscular junction (NMJ) overgrowth phenotype and that manipulations that increase cAMP/PKA signaling in adipokinetic hormone (AKH)-producing cells at the base of the neuroendocrine ring gland restore the dNf1 growth deficiency. Finally, supporting our previous contention that ALK might be a therapeutic target in NF1, we report that human ALK is expressed in cells that give rise to NF1 tumors and that NF1 regulated ALK/RAS/ERK signaling appears conserved in man. Neurofibromatosis type 1 (NF1) is a genetic disease that affects 1 in 3,000 and that is caused by loss of a protein that inactivates Ras oncoproteins. NF1 is a characteristically variable disease that predisposes patients to several symptoms, the most common of which include benign and malignant tumors, reduced growth and learning problems. We and others previously found that fruit fly mutants that lack a highly conserved dNf1 gene are reduced in size and exhibit impaired learning and memory, and that both defects appear due to abnormal Ras and cyclic-AMP (cAMP) signaling. The former was unremarkable, but how loss of dNf1 affects cAMP signaling remains poorly understood. Here we report results of a genetic screen for dominant modifiers of the dNf1 growth defect. This screen and follow-up functional studies support a model in which synaptic defects and reduced cAMP signaling in specific parts of the neuroendocrine ring gland contribute to the dNf1 growth defect. Beyond these results, we show that human ALK is expressed in cells that give rise to NF1 tumors, and that NF1 regulated ALK/RAS/ERK signaling is evolutionary conserved.

5 September 2019 in The Journal of Neuroscience
Verified
Journal Article
Open access
PDF file
KPKaterina Papanikolopoulou
Katerina Papanikolopoulou
IRIlianna G. Roussou
Ilianna G. Roussou
JGJean Y. Gouzi
Jean Y. Gouzi
MSMartina Samiotaki
Martina Samiotaki
GPGeorge Panayotou
George Panayotou
Efthimios M.C. SkoulakisEfthimios M.C. Skoulakis
Efthimios M.C. Skoulakis
Although the involvement of pathological tau in neurodegenerative dementias is indisputable, its physiological roles have remained elusive in part because its abrogation has been reported without overt phenotypes in mice andDrosophila. This was addressed using the recently describedDrosophila tauKOand Mi{MIC} mutants and focused on molecular and behavioral analyses. Initially, we show thatDrosophilatau (dTau) loss precipitates dynamic cytoskeletal changes in the adultDrosophilaCNS and translation upregulation. Significantly, we demonstrate for the first time distinct roles for dTau in adult mushroom body (MB)-dependent neuroplasticity as its downregulation within α′β′neurons impairs habituation. In accord with its negative regulation of translation, dTau loss specifically enhances protein synthesis-dependent long-term memory (PSD-LTM), but not anesthesia-resistant memory. In contrast, elevation of the protein in the MBs yielded premature habituation and depressed PSD-LTM. Therefore, tau loss inDrosophiladynamically alters brain cytoskeletal dynamics and profoundly affects neuronal proteostasis and plasticity.SIGNIFICANCE STATEMENTWe demonstrate that despite modest sequence divergence, theDrosophilatau (dTau) is a true vertebrate tau ortholog as it interacts with the neuronal microtubule and actin cytoskeleton. Novel physiological roles for dTau in regulation of translation, long-term memory, and footshock habituation are also revealed. These emerging insights on tau physiological functions are invaluable for understanding the molecular pathways and processes perturbed in tauopathies.

25 January 2007 in FEBS Letters
Verified
Journal Article
Closed access
JDJoffrey Degoutin
Joffrey Degoutin
MVMarc Vigny
Marc Vigny
JGJean Y. Gouzi
Jean Y. Gouzi

15 December 2005 in Journal of Cell Science
Verified
Journal Article
Open access
PDF file
JGJean Y. Gouzi
Jean Y. Gouzi
CMChristel Moog-Lutz
Christel Moog-Lutz
MVMarc Vigny
Marc Vigny
NCNicole Brunet-De Carvalho
Nicole Brunet-De Carvalho
Anaplastic lymphoma kinase (ALK) is a receptor tyrosine kinase essentially and transiently expressed in specific areas of the developing central and peripheral nervous systems. We previously demonstrated that a membrane-bound and constitutively active form of the ALK protein tyrosine kinase (PTK) domain induced the neuron-like differentiation of PC12 cells through specific activation of the mitogen-activated protein kinase (MAP kinase) pathway. Its PTK domain had been originally identified in a nucleo-cytosolic and constitutively active transforming protein, NPM-ALK. Downstream targets involved in oncogenic proliferation and survival processes have been proposed to include phospholipase Cγ (PLCγ), phosphoinositide 3-kinase (PI 3-kinase)/AKT, STAT 3/5 and Src. We therefore postulated that activation of specific signaling pathways leading to differentiation or proliferation can be differently controlled depending on the subcellular localization of ALK PTK domain. To increase knowledge of its physiological role in the nervous system, we focused in the present study on the influence of its subcellular localization on neuronal differentiation. To achieve this goal, we characterized biological responses and transduction pathways in PC12 cells elicited by various constructs encoding membrane-bound (through transmembrane or myristyl sequences) or cytosolic ALK-derived proteins. In order to control the activation of their PTK domain, we used an inducible dimerization system. Here, we demonstrate that membrane attachment of the ALK PTK domain, in PC12 cells, is crucial for initiation of neurite outgrowth and proliferation arrest through a decrease of DNA synthesis. Furthermore, we show that this differentiation process relies on specific and sustained activation of ERK 1/2 proteins. By contrast, activation of the cytosolic form of this domain fails to induce MAP kinase activation and cell differentiation but promotes a PI 3-kinase/AKT-dependant PC12 cell proliferation. These data indicate that subcellular localization of the ALK PTK domain was a determinant for the control and specificity of downstream transduction cascades and was crucial for deciding the fate to which the neuronal cell will be committed.